A U.S. cannabis company has expressed interest in acquiring Aurora Cannabis Inc., a firm based in Edmonton. Aurora revealed that it will set up a special committee to review the unsolicited bid made by Curaleaf Holdings Inc. The potential acquisition aims to create a joint cannabis enterprise with operations in 17 countries worldwide. Despite attempts to negotiate privately, Curaleaf decided to publicize its proposal after Aurora’s board declined to engage in discussions following the submission of formal letters outlining the offer.
Curaleaf proposed to pay Aurora shareholders $4 US per share along with an additional $0.75 US cash for each share. Aurora acknowledged receiving the letters from Curaleaf but disputed the claim that it had refused to consider the offer. The Canadian company stated that it had ongoing communication with Curaleaf’s CEO and emphasized its commitment to executing its business plan in the short to medium term.
Aurora plans to establish an independent committee to evaluate the proposal’s alignment with stakeholder interests. However, it emphasized that there is no certainty of a deal being finalized and reassured that its operations will continue as usual during the process. While recognizing Curaleaf’s interest, TD Cowen analysts expressed a belief that the current offer undervalues Aurora’s potential for long-term growth.
Curaleaf’s CEO highlighted the potential benefits of merging the companies, emphasizing the value created by combining global distribution capabilities with Aurora’s established medical cannabis presence and production capacity. The projected annual revenue of over $1.5 billion US from the combined entities and expected cost synergies of $40 million US further underscored the strategic rationale behind the proposed acquisition.
The merger is seen as a mutually beneficial opportunity for shareholders of both companies, providing a more diversified global platform and increased exposure to favorable U.S. regulatory trends.